Discontinue use if severe hepatotoxicity develops. HTN, hypokalaemia or fluid retention; heart failure, recent MI or ventricular arrhythmia, QT prolongation, Torsade de pointes; decreased bone density. History of CV disease. Patients subjected to unusual stress & corticosteroid w/drawal. Monitor serum transaminases & bilirubin levels every 2 wk for 1st 3 mth & mthly thereafter; BP, serum K & fluid retention mthly. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not to be initiated w/ Ra-223 for at least 5 days after last dose. Concomitant use w/ chemotherapy; ketoconazole. Severe renal & moderate hepatic impairment. Not to be used in severe hepatic impairment. Not to be used in women.